Twenty-Two Million on Three Point Three Billion

Twenty-two million dollars. That was the operating profit Temple University Health System reported on $3.3 billion of revenue for the year ended June 30, 2025 - a margin of roughly seven tenths of one percent. It was a good year. The year before, the same system had cleared $973,000.

Then came the arithmetic that mattered more. Temple said it anticipated losing $30 million to $90 million annually because of changes to Medicaid in the federal law enacted that July. Against a $22 million operating profit, the low end of that range erases the year. The high end is four times it.

On January 2, 2026, Abhinav Rastogi took the chief executive's seat.

Twenty Years, Nine Different Seats

Rastogi did not arrive from a consultancy or a rival system. He had been at Temple for more than two decades, and the record of what he did there is unusually granular for a hospital executive.

He came out of engineering and technology consulting - project team leader at Tata Infotech, then a consultant at IBM - and entered Temple through its School of Pharmacy as a pharmaco-economic data analyst. From there: director of the Project Management Office. Associate hospital director of the pulmonary service line. Senior vice president of professional services. In July 2020, executive vice president of the health system and chief operating officer of Temple University Hospital.

That last promotion is worth sitting with. July 2020 was not a quiet moment to take operational control of a North Philadelphia teaching hospital.

Eighteen months later, on January 1, 2022, he was named president and chief executive of Temple University Hospital. Michael A. Young, then running the system, gave the reason in the announcement, and it was not about vision. It was about the ledger: Rastogi had, Young said, "thorough familiarity with the day-to-day operational and financial performance of Temple University Hospital."

Familiarity is a modest word for what a health system needs when it earns less than a penny on the dollar.

What He Did With The Hospital

The hospital he ran is not one building. It is Main Campus, Jeanes Campus, Episcopal Campus, Temple Women & Families Hospital and Temple Health-Chestnut Hill Hospital.

Temple's own account of his tenure there credits him with more than $100 million in annual impact through operational and financial improvements, and with a pivotal role in the performance of Chestnut Hill and the launch of Temple Women & Families Hospital. In the same period the Temple Lung Center became what the health system describes as the nation's highest volume lung transplant program.

Those are two different kinds of achievement, and they pull against each other. Complex transplant medicine is expensive to run and reputationally decisive. Operational savings are invisible to patients and existential to the balance sheet. Rastogi's twenty years were spent on the second while the institution built the first.

The Succession Was Planned

There was no search firm and no shortlist made public. On October 30, 2025, Temple University President John Fry announced that Rastogi would succeed Young - who was retiring - under what Temple called its established succession plan, with the change to be executed on January 2, 2026.

Fry's framing was continuity, stated plainly: "Abhi is a Temple Made leader. This internal transition demonstrates stability, strength, and continuity of purpose at Temple Health."

Young, handing over after nearly six years in the system seat, said Temple was "strongly positioned for the future, and Abhi is the right leader to continue our strategic path and build on what we have already achieved."

Rastogi's own statement put the weight somewhere other than strategy. "Temple Health is strong because of its people. We play different roles, but we are united by a deep commitment to our patients," he said, thanking Young for his mentorship and Fry for his confidence.

Then he did something a caretaker would not have done.

He Kept Both Jobs

Rastogi continues to lead Temple University Hospital while serving as chief executive of the health system. Temple's leadership directory lists both titles against his name.

Holding an operating job and the corporate job at once is a choice with consequences in either direction. It concentrates decision-making in a year when the payer environment is about to move against the institution. It also means the person setting system strategy is still accountable for the largest single asset's results, with no layer of translation in between.

The complication is not hypothetical, and it is not new. Temple's fiscal 2025 gain came substantially from outpatient growth, much of it from its pharmacy business, and from a $69.2 million increase in state funding - not from the core inpatient economics of a safety-net academic medical center. The system had been losing money under its Medicaid contract with Jefferson Health Plans. Cash reserves stood at $1 billion on June 30, 2025, up from $943.9 million a year earlier, which buys time and does not buy margin.

What The First Year Measures

Rastogi inherited an institution that has just proved it can make money, in a policy environment specifically designed to make that harder, in a neighborhood where the payer mix is not going to improve.

The numbers that will judge him are already on the record and already dated. A $22 million operating profit. A $30 million to $90 million annual Medicaid exposure. A billion dollars of cash. Twenty years of institutional knowledge, now spent from the top instead of the middle.

He said Temple Health is strong because of its people. The fiscal year that ends June 30, 2026 will say what that is worth in dollars.